Trial summary
This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors. The main questions it aims to answer are:
What is the safety profile of MT-304 when administered alone or with nivolumab?
What is the recommended Phase 2 dose (RP2D) of MT-304?
Participants will:
Receive MT-304 alone (every 14 days) or with nivolumab (every 28 days).
Attend regular clinic visits for assessments and monitoring.
Continue treatment until disease progression, unacceptable toxicity, or study discontinuation.
Trial details
Short title
MTX-HER2-304
Diagnosis
Advanced solid tumours
Type of treatment
Medical Oncology
Phase
I
Locations
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.